-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.
-
Automated insulin delivery demonstrates efficacy in glycemic management in the hospital
Francisco Pasquel, MD, MPH, and other panelists presented new data from the AIDING trial, which compared automated inulin delivery to multiple daily injections combined with continuous glucose monitoring in individuals with type 1 diabetes or type 2 diabetes during hospitalization.
-
Discussion to consider pragmatic solutions through diabetes technology across diverse demographics and settings
Michelle Litchman, PhD, APRN, FNP-BC, and other experts will examine data, challenges, and best practices around the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) devices among children, older adults, the Deaf community, and inpatient populations.
-
Joint ADA/IDF symposium to address malnutrition-related diabetes diagnosis, treatment, and research needs
Peter E. H. Schwarz, MD, PhD, MBA, and other leading experts from across the globe will discuss the latest information on the prevention, diagnosis, and treatment of what an international working group has designated as type 5 or malnutrition-related diabetes.
-
Debate to weigh speed of AI adoption in diabetes care
Nestoras Mathioudakis, MD, MHS, and Neda Laiteerapong, MD, will debate the merits of incorporating artificial intelligence (AI) into health care delivery now versus taking a wait-and-see approach. They will discuss cost and quality of care and clinician burnout as key factors to consider.
-
Dual GLP-1/GIP receptor agonist improves glycemic management and weight loss in adults living with type 1 diabetes and obesity
Klara Klein, MD, PhD, and other researchers shared results from a phase 2, double-blind, randomized study of acmopatide. Study participants also experienced improvements in blood pressure and insulin dosing.
-
Positive data from multiple amylin trials draw focus to novel therapeutic mechanism
Investigators, including Carel le Roux, MBChB, FRCP, FRCPath, PhD, discussed findings from monotherapy and combination trials with the pancreatic beta cell hormone. “Not only are these weight loss drugs, these are also health-gain drugs,” Dr. le Roux said.
-
Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
A Scientific Sessions panel shared new data from the VESPER trials. The long half-life of berobenatide makes investigators optimistic about its potential for monthly dosing.
-
Year in Review symposium to deliver the latest discoveries in diabetes
Anne Peters, MD, will highlight major advances and discoveries in the clinical science of diabetes, including expanding treatment and technology options. Raghu Mirmira, MD, PhD, will summarize translational progress, and Barbara Kahn, MD, will share basic science developments.
-
Symposium to introduce novel approaches to harnessing tech in diabetes management
One of the panelists, Anna Kahkoska, MD, PhD, will explain how to leverage electronic health records to automate diabetes distress screening and facilitate practitioner conversations.